Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of DOC1021 in Refractory Melanoma

Next Previous
Trial Profile

A Phase 1/2 Study of DOC1021 in Refractory Melanoma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dubodencel (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 22 Dec 2025 New trial record
  • 10 Dec 2025 According to a Diakonos Oncology media release, enrollment in the Phase 1 part of this clinical study is expected to begin in January 2026.
  • 10 Dec 2025 According to a Diakonos Oncology media release, the company has received a Product Development Research Grant exceeding $7 million through The Cancer Prevention and Research Institute of Texas (CPRIT). This funding will support advancing DOC1021 into a Phase 1/2 clinical trial for patients with refractory melanoma.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top